Form DEF 14A PharmaCyte Biotech For: 9 March
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
PharmaCyte Biotech Inc (PMCB)
PharmaCyte Biotech Inc stock price live, this page displays NASDAQ PMCB stock exchange data. View the PMCB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the PharmaCyte Biotech Inc real time stock price chart below.
What Is the PharmaCyte Biotech Inc Stock Price Today?
The PharmaCyte Biotech Inc stock price today is 0.5954.
What Is the Stock Symbol for PharmaCyte Biotech Inc?
The stock symbol for PharmaCyte Biotech Inc is "PMCB."
What Stock Exchange Does PharmaCyte Biotech Inc Trade On?
PharmaCyte Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is PharmaCyte Biotech Inc a Good Stock to Buy?
Determining whether PharmaCyte Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PMCB quote. (ISIN: US71715X2036)
What Is the PharmaCyte Biotech Inc Stock Price Today?
The PharmaCyte Biotech Inc stock price today is 0.5954.
What Is the Stock Symbol for PharmaCyte Biotech Inc?
The stock symbol for PharmaCyte Biotech Inc is "PMCB."
What Stock Exchange Does PharmaCyte Biotech Inc Trade On?
PharmaCyte Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is PharmaCyte Biotech Inc a Good Stock to Buy?
Determining whether PharmaCyte Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PMCB quote. (ISIN: US71715X2036)
NASDAQ
Currency in USD
0.5954
+0.0054(+0.92%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5850
0.5954
52 wk Range
0.5500
1.5100
PMCB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.58500.5954
52 wk Range
0.55001.5100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PMCB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form PRE 14A PharmaCyte Biotech For: 27 February- Investing.com
Form DEF 14A PharmaCyte Biotech Inc For: 17 November- Investing.com
- Form DEF 14A PharmaCyte Biotech For: 9 March
- Investing.com
- Form PRE 14A PharmaCyte Biotech For: 27 February
- Investing.com
- Pharmacyte Biotech CEO Silverman buys $80k in shares
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Earnings
Latest Release
Jul 01, 2026
EPS / Forecast
-0.46 / --
Revenue / Forecast
-- / --
Compare PMCB to Peers and Sector
Metrics to compare | PMCB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPMCBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −4.2x | −0.4x | |
PEG Ratio | 0.00 | −0.04 | 0.00 | |
Price/Book | 0.2x | 1.5x | 2.6x | |
Price / LTM Sales | - | 29.9x | 3.0x | |
Upside (Analyst Target) | - | 183.6% | 51.8% | |
Fair Value Upside | Unlock | 3.9% | 7.2% | Unlock |
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the PharmaCyte Biotech (PMCB) Stock Price Today?
The PharmaCyte Biotech stock price today is 0.5954 USD.
What Stock Exchange Does PharmaCyte Biotech Trade On?
PharmaCyte Biotech is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for PharmaCyte Biotech?
The stock symbol for PharmaCyte Biotech is "PMCB."
What Is the PharmaCyte Biotech Market Cap?
As of today, PharmaCyte Biotech market cap is 6.3400M USD.
What Is PharmaCyte Biotech's Earnings Per Share (TTM)?
The PharmaCyte Biotech EPS (TTM) is -2.7698.
When Is the Next PharmaCyte Biotech Earnings Date?
PharmaCyte Biotech will release its next earnings report on Aug 24, 2026.
From a Technical Analysis Perspective, Is PMCB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has PharmaCyte Biotech Stock Split?
PharmaCyte Biotech has split 2 times.
How Many Employees Does PharmaCyte Biotech Have?
PharmaCyte Biotech has 2 employees.
What is the current trading status of PharmaCyte Biotech (PMCB)?
As of Aug 06, 2026, PharmaCyte Biotech (PMCB) is trading at a price of 0.5954 USD, with a previous close of 0.5900 USD. The stock has fluctuated within a day range of 0.5850 USD to 0.5954 USD, while its 52-week range spans from 0.5500 USD to 1.5100 USD.
What Is the PMCB After Hours Price?
PMCB's last after hours stock price is 0.5800 USD, the stock has decreased by -0.0100, or -1.6900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.